Evolution and immediate future of US screening guidelines

Kirsten L. Greene; Sanoj Punnen; Peter R. Carroll

doi:10.1016/j.ucl.2014.01.005

Evolution and immediate future of US screening guidelines

Kirsten L. Greene, Sanoj Punnen, Peter R. Carroll

Research output: Contribution to journal › Review article

3 Scopus citations

Abstract

Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.

Original language	English (US)
Pages (from-to)	229-235
Number of pages	7
Journal	Urologic Clinics of North America
Volume	41
Issue number	2
DOIs	https://doi.org/10.1016/j.ucl.2014.01.005
State	Published - May 2014
Externally published	Yes

Keywords

Guidelines
Prostate cancer
Prostate specific antigen (PSA)
Public health
Screening

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.ucl.2014.01.005

Fingerprint Dive into the research topics of 'Evolution and immediate future of US screening guidelines'. Together they form a unique fingerprint.

Cite this

Greene, K. L., Punnen, S., & Carroll, P. R. (2014). Evolution and immediate future of US screening guidelines. Urologic Clinics of North America, 41(2), 229-235. https://doi.org/10.1016/j.ucl.2014.01.005

@article{c2927b32b6ba43db8a1f70e8b6ffcb1f,

title = "Evolution and immediate future of US screening guidelines",

abstract = "Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.",

keywords = "Guidelines, Prostate cancer, Prostate specific antigen (PSA), Public health, Screening",

author = "Greene, {Kirsten L.} and Sanoj Punnen and Carroll, {Peter R.}",

year = "2014",

month = may,

doi = "10.1016/j.ucl.2014.01.005",

language = "English (US)",

volume = "41",

pages = "229--235",

journal = "Urologic Clinics of North America",

issn = "0094-0143",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Evolution and immediate future of US screening guidelines

AU - Greene, Kirsten L.

AU - Punnen, Sanoj

AU - Carroll, Peter R.

PY - 2014/5

Y1 - 2014/5

N2 - Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.

AB - Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.

KW - Guidelines

KW - Prostate cancer

KW - Prostate specific antigen (PSA)

KW - Public health

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84898029953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898029953&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2014.01.005

DO - 10.1016/j.ucl.2014.01.005

M3 - Review article

C2 - 24725485

AN - SCOPUS:84898029953

VL - 41

SP - 229

EP - 235

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 2

ER -